MISSISSAUGA, ON, Jan. 16 /PRNewswire-FirstCall/ -- Vasogen Inc. (NASDAQ:VSGN; TSX:VAS), today reported the results of operations for the fiscal year ended November 30, 2007. All dollar amounts referenced herein are in Canadian dollars unless otherwise noted. At November 30, 2007, our cash and cash equivalents totaled $23.5 million, compared with $30.4 million at November 30, 2006. The change in our cash position resulted mainly from cash used for operations partially offset by cash provided by financing activities. Our net cash used for operations for the three months ended November 30, 2007, was $4.5 million. The net loss for the fourth quarter of 2007 was $6.1 million, or $0.27 per common share. We incurred a net loss for the year ended November 30, 2007 of $28.8 million, or $1.46 per common share, compared with a net loss of $66.4 million, or $7.05 per common share for the same period in 2006. The key drivers of our reduced losses in 2007 are lower research and development expenses as a result of the completion of our phase III clinical programs in 2006, the corporate costs associated with supporting these programs, and a reduction in expenses associated with our senior convertible notes. These reductions in expenses were partially offset by restructuring costs. The difference between cash used in operations and our accounting loss is driven by non-cash items, such as expenses related to our senior convertible notes and stock options, as well as unrealized foreign exchange gains and losses. Highlights - The results from the phase III ACCLAIM trial of our Celacade(TM) System in patients with chronic heart failure were accepted for publication in The Lancet, a world-leading medical journal. As previously reported by Vasogen, while the trial did not meet its primary endpoint, a key finding from the ACCLAIM trial was a 39% reduction in the risk of death or cardiovascular hospitalizations for a large pre-specified subgroup of patients with NYHA Class II heart failure who received Celacade therapy, compared to patients receiving placebo. - We entered into a collaboration with Grupo Ferrer Internacional, S.A., a leading European pharmaceutical and medical devices company, to commercialize Celacade for the treatment of chronic heart failure in specified countries of the European Union and in certain Latin American countries. In December 2007, Ferrer received initial orders for Celacade in Germany. - The Food and Drug Administration strongly recommended that we conduct a confirmatory study (ACCLAIM-II) in NYHA Class II heart failure patients to support a Pre-market Approval filing for Celacade in the United States. The FDA also recommended that we utilize a Bayesian statistical approach for designing the confirmatory trial as it would allow for the borrowing of statistical power from the ACCLAIM study. This approach has the potential to substantially reduce the number of patients required for a confirmatory study, as well as the cost and duration. - James B. Young, MD, Chairman, Division of Medicine at the Cleveland Clinic Foundation and Medical Director, Kaufman Center for Heart Failure, was appointed the Global Principal Investigator and Chairman of the Steering Committee for ACCLAIM-II. - Chris Waddick, MBA, CMA, was appointed President, CEO, and a Member of the Board of Directors of our Company. Mr. Waddick has held a series of progressive senior management positions at Vasogen over the past twelve years, most recently as Chief Operating Officer and Chief Financial Officer. As previously announced, a conference call will be conducted on January 16, 2008, at 4:30 p.m. Eastern Time. The conference call may be accessed by calling 416-641-6142 or 1-866-542-4241 ten minutes prior to the call. An audio web cast of the event will also be available at http://www.vasogen.com/. A re-broadcast of the conference call may be accessed by calling 416-695-5800 or 1-800-408-3053, pass code 3248350 followed by the number sign, and will also be available at http://www.vasogen.com/. About Vasogen: Vasogen is a biotechnology company engaged in the research and commercial development of therapies designed to target the destructive inflammatory process associated with the development and progression of cardiovascular and neurodegenerative disorders. The Company's lead product, the Celacade(TM) System, is designed to activate the immune response to apoptosis - an important physiological process that regulates inflammation. Celacade has received European regulatory approval under the CE Mark for chronic heart failure and is being marketed in the EU by Grupo Ferrer Internacional, S.A. Celacade is also in late-stage clinical development for the treatment of chronic heart failure in the United States. Vasogen is also developing a new class of drugs for the treatment of certain neuro-inflammatory disorders. VP025 is the lead candidate from this new class of drugs. Certain statements contained in this press release, the upcoming conference call and webcast, or elsewhere in our public documents constitute "forward-looking statements" within the meaning of the United States Private Securities Litigation Reform Act of 1995 and/or "forward-looking information" under the Securities Act (Ontario). These statements may include, without limitation, plans to advance the development of Celacade(TM) or VP025, plans to fund our current activities, statements concerning our partnering activities, health regulatory submissions, strategy, future operations, future financial position, future revenues and projected costs. In some cases, you can identify forward-looking statements by terminology such as "may", "will", "should", "expects", "plans", "anticipates", "believes", "estimated", "predicts", "potential", "continue", "intends", "could", or the negative of such terms or other comparable terminology. We made a number of assumptions in the preparation of these forward-looking statements, including assumptions about the nature, size, and accessibility of the market for Celacade in the treatment of chronic heart failure, particularly in Europe, the regulatory approval process leading to commercialization and the availability of capital on acceptable terms to pursue the development of Celacade, and the feasibility of additional trials. You should not place undue reliance on our forward-looking statements which are subject to a multitude of risks and uncertainties that could cause actual results, future circumstances or events to differ materially from those projected. These risks include, but are not limited to, the outcome of further ongoing analysis of the ACCLAIM trial results, the requirement or election to conduct additional clinical trials and the size and design of any such trials, delays or setbacks in the regulatory approval process, difficulties in the maintenance of existing regulatory approvals, securing and maintaining corporate alliances, the need for additional capital and the effect of capital market conditions and other factors on capital availability, the potential dilutive effects of any financing, risks associated with the outcomes of our preclinical and clinical research and development programs, the adequacy, timing, and results of our clinical trials, competition, market acceptance of our products, the availability of government and insurance reimbursements for our products, the strength of intellectual property, reliance on partners, subcontractors, and key personnel, losses due to fluctuations in the U.S.-Canadian exchange rate, and other risks detailed from time to time in our public disclosure documents or other filings with the Canadian and U.S. securities commissions or other securities regulatory bodies. Additional risks and uncertainties relating to our Company and our business can be found in the "Risk Factors" section of our Annual Information Form and Form 20-F for the year ended November 30, 2006, as well as in our later public filings. The forward-looking statements are made as of the date hereof, and we disclaim any intention and have no obligation or responsibility, except as required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. The consolidated financial statements, accompanying notes to the consolidated financial statements, and Management's Discussion and Analysis for the year ended November 30, 2007, will be accessible on Vasogen's web site at http://www.vasogen.com/ and will be available on SEDAR and EDGAR. Financial statements are provided below. VASOGEN INC. (A DEVELOPMENT STAGE COMPANY) Consolidated Balance Sheets (In thousands of Canadian dollars) November 30, 2007 and 2006 ------------------------------------------------------------------------- 2007 2006 ------------------------------------------------------------------------- Assets Current assets: Cash and cash equivalents $ 23,545 $ 30,427 Restricted cash - 6,403 Clinical supplies 1,363 1,211 Tax credits recoverable 1,565 1,327 Prepaid expenses and deposits 787 1,384 Change in fair value of forward foreign exchange contracts 376 - ----------------------------------------------------------------------- 27,636 40,752 Property and equipment 414 615 Acquired technology - 253 Deferred financing costs - 150 ------------------------------------------------------------------------- $ 28,050 $ 41,770 ------------------------------------------------------------------------- ------------------------------------------------------------------------- Liabilities and Shareholders' Equity Current liabilities: Accounts payable $ 1,175 $ 3,369 Accrued liabilities 3,519 5,067 Current portion of senior convertible notes payable - 8,754 ----------------------------------------------------------------------- 4,694 17,190 Shareholders' equity: Share capital: Authorized: Unlimited common shares, without par value Issued and outstanding: 22,391,386 common shares (2006 - 15,665,134) 365,670 344,217 Warrants 16,725 11,390 Contributed surplus 22,744 20,347 Deficit (381,783) (351,374) ----------------------------------------------------------------------- 23,356 24,580 $ 28,050 $ 41,770 ------------------------------------------------------------------------- ------------------------------------------------------------------------- VASOGEN INC. (A DEVELOPMENT STAGE COMPANY) Consolidated Statements of Operations, Deficit and Comprehensive Income (In thousands of Canadian dollars, except per share amounts) ------------------------------------------------------------------------- Period from December 1, 1987 to Years ended November 30, November 30, 2007 2006 2005 2007 ------------------------------------------------------------------------- Expenses: Research and development $ 12,039 $ 32,732 $ 71,421 $ 238,917 General and administration 14,259 19,251 22,126 117,228 Foreign exchange loss (gain) 1,977 104 (719) 10,970 ------------------------------------------------------------------------- Loss before the undernoted (28,275) (52,087) (92,828) (367,115) Interest expense on senior convertible notes payable (5) (930) (344) (1,279) Accretion in carrying value of senior convertible notes payable (728) (7,824) (1,742) (10,294) Amortization of deferred financing costs (154) (2,495) (408) (3,057) Loss on extinguishment of senior convertible notes payable (1,754) (4,995) - (6,749) Investment income 1,310 1,971 2,274 13,325 Change in fair value of embedded derivatives 829 - - 829 ------------------------------------------------------------------------- Loss and comprehensive loss for the period (28,777) (66,360) (93,048) (374,340) Deficit, beginning of period: As originally reported (351,374) (284,719) (187,665) (1,510) Impact of change in accounting for stock- based compensation - - (4,006) (4,006) Impact of change in accounting for financial instruments on December 1, 2006 (1,632) - - (1,632) ----------------------------------------------------------- As revised (353,006) (284,719) (191,671) Charge for acceleration payments on equity component of senior convertible notes payable - (295) - (295) ------------------------------------------------------------------------- Deficit, end of period $(381,783) $(351,374) $(284,719) $(381,783) ------------------------------------------------------------------------- ------------------------------------------------------------------------- Basic and diluted loss per common share $ (1.46) $ (7.05) $ (11.65) ------------------------------------------------------------------------- ------------------------------------------------------------------------- VASOGEN INC. (A DEVELOPMENT STAGE COMPANY) Consolidated Statements of Cash Flows (In thousands of Canadian dollars) ------------------------------------------------------------------------- Period from December 1, 1987 to Years ended November 30, November 30, 2007 2006 2005 2007 ------------------------------------------------------------------------- Cash provided by (used in): Operating activities: Loss for the period $ (28,777) $ (66,360) $ (93,048) $(378,346) Items not involving cash: Amortization 503 782 589 6,160 Accretion in carrying value of senior convertible notes payable 728 7,824 1,742 10,294 Amortization of deferred financing costs 154 2,495 408 3,057 Loss on extinguishment of senior convertible notes payable 1,754 4,995 - 6,749 Change in fair value of embedded derivatives (829) - - (829) Stock-based compensation 1,995 3,083 3,615 13,585 Common shares issued for services - 36 - 2,485 Unrealized gain on forward foreign exchange contract (376) - - (376) Unrealized foreign exchange loss (gain) 2,566 (65) (542) 11,543 Other - - - (35) Change in non-cash operating working capital (3,535) (17,158) 12,634 951 ----------------------------------------------------------------------- (25,817) (64,368) (74,602) (324,762) Financing activities: Shares and warrants issued for cash 17,345 23,106 52,502 326,358 Warrants exercised for cash - - - 16,941 Options exercised for cash - - 627 7,669 Share issue costs (1,440) (2,221) (3,720) (24,646) Issue (repayment) of senior convertible notes payable, net (924) (3,976) 42,790 38,512 Cash released from (placed under) restriction 6,403 5,298 (11,701) - Paid to related parties - - - (234) ----------------------------------------------------------------------- 21,384 22,207 80,498 364,600 Investing activities: Purchases of property and equipment (49) (23) (490) (2,465) Purchases of acquired technology - - - (1,283) Purchases of marketable securities - (80) (22,999) (244,846) Settlement of forward exchange contracts 10 (102) (4,732) (4,824) Maturities of marketable securities - 23,079 67,651 240,677 ----------------------------------------------------------------------- (39) 22,874 39,430 (12,741) Foreign exchange loss on cash held in foreign currency (2,410) (807) (141) (3,552) ------------------------------------------------------------------------- Increase (decrease) in cash and cash equivalents (6,882) (20,094) 45,185 23,545 Cash and cash equivalents, beginning of period 30,427 50,521 5,336 - ------------------------------------------------------------------------- Cash and cash equivalents, end of period $ 23,545 $ 30,427 $ 50,521 $ 23,545 ------------------------------------------------------------------------- ------------------------------------------------------------------------- DATASOURCE: Vasogen Inc. CONTACT: Glenn Neumann, Investor Relations, 2505 Meadowvale Blvd., Mississauga, ON, Canada, L5N 5S2, tel: (905) 817-2004, fax: (905) 569-9231, http://www.vasogen.com/,

Copyright